SHBG Inhibitors
SHBG inhibitors comprise a diverse class of chemicals that intricately modulate the expression of Sex Hormone-Binding Globulin (SHBG), a critical regulator of sex hormone bioavailability. These inhibitors exert their effects through direct interactions with androgen or estrogen receptors or by modulating the biosynthesis of sex hormones. Flutamide, an androgen receptor antagonist, competes with endogenous androgens for binding, leading to reduced androgen signaling and subsequent downregulation of SHBG. Ketoconazole disrupts steroidogenesis by inhibiting cytochrome P450 enzymes, diminishing androgen production and indirectly influencing SHBG expression. Danazol, another androgen derivative, competes with endogenous androgens, reducing androgen receptor-mediated transcription, including SHBG.
Dihydrotestosterone (DHT), a potent androgen, directly affects SHBG levels by serving as a ligand for the androgen receptor, inducing the transcription of androgen-responsive genes. Mifepristone, a synthetic steroid, interferes with glucocorticoid receptor signaling, inhibiting the transcriptional activation of glucocorticoid-responsive genes, including SHBG. Finasteride alters androgen metabolism by inhibiting 5-alpha-reductase, reducing the availability of potent androgens that activate SHBG. Spironolactone, a mineralocorticoid receptor antagonist, competes with androgens for binding to the androgen receptor, leading to decreased androgen signaling and downregulation of SHBG. Anastrozole, an aromatase inhibitor, modulates SHBG levels by impacting estrogen biosynthesis, altering estrogen receptor-mediated transcription. Cyproterone Acetate, an anti-androgenic progestin, competes with androgens for binding to the androgen receptor, reducing androgen signaling and influencing SHBG expression. Clomiphene and Tamoxifen, selective estrogen receptor modulators (SERMs), disrupt estrogen receptor-mediated transcription, indirectly affecting SHBG levels. Letrozole, another aromatase inhibitor, modulates SHBG expression by impacting estrogen biosynthesis. These inhibitors collectively provide insights into the intricate regulatory networks governing SHBG dynamics, emphasizing the interconnectedness of sex hormone pathways in shaping its expression.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Flutamide | 13311-84-7 | sc-204757 sc-204757A sc-204757D sc-204757B sc-204757C | 1 g 5 g 25 g 500 g 1 kg | $46.00 $153.00 $168.00 $515.00 $923.00 | 4 | |
Flutamide, an androgen receptor antagonist, indirectly influences SHBG levels by inhibiting androgen signaling. By competing with androgens for binding to the androgen receptor, flutamide reduces the activation of androgen-responsive genes, including SHBG. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
Ketoconazole, an antifungal agent in research, indirectly modulates SHBG levels by inhibiting steroidogenesis. It interferes with cytochrome P450 enzymes involved in steroid hormone synthesis, leading to reduced androgen production. Consequently, the diminished androgen levels contribute to the downregulation of SHBG expression. | ||||||
Danazol | 17230-88-5 | sc-203021 sc-203021A | 100 mg 250 mg | $90.00 $233.00 | 3 | |
Danazol, a synthetic androgen derivative, indirectly influences SHBG expression by modulating androgen receptor activity. Similar to flutamide, danazol competes with endogenous androgens for binding to the androgen receptor, resulting in decreased androgen signaling. | ||||||
Mifepristone | 84371-65-3 | sc-203134 | 100 mg | $60.00 | 17 | |
Mifepristone, a synthetic steroid, indirectly modulates SHBG by interfering with glucocorticoid receptor signaling. It acts as a glucocorticoid receptor antagonist, inhibiting the transcriptional activation of glucocorticoid-responsive genes, including SHBG. | ||||||
Finasteride | 98319-26-7 | sc-203954 | 50 mg | $103.00 | 3 | |
Finasteride, a 5-alpha-reductase inhibitor, indirectly impacts SHBG levels by altering androgen metabolism. By inhibiting the conversion of testosterone to dihydrotestosterone (DHT), finasteride reduces the availability of potent androgens that activate androgen receptor-mediated transcription, including SHBG. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $107.00 | 3 | |
Spironolactone, a mineralocorticoid receptor antagonist, indirectly influences SHBG levels through anti-androgenic effects. It competes with androgens for binding to the androgen receptor, leading to decreased androgen signaling. | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $90.00 | 1 | |
Anastrozole, an aromatase inhibitor, indirectly modulates SHBG levels by impacting estrogen biosynthesis. By inhibiting aromatase, Anastrozole reduces the conversion of androgens to estrogens, leading to altered estrogen levels. | ||||||
Cyproterone Acetate | 427-51-0 | sc-204703 sc-204703A | 100 mg 250 mg | $60.00 $199.00 | 5 | |
Cyproterone Acetate, an anti-androgenic progestin, indirectly influences SHBG levels by antagonizing androgen receptor activity. By competing with androgens for binding to the androgen receptor, Cyproterone Acetate reduces androgen signaling. | ||||||
Clomiphene Citrate | 50-41-9 | sc-205636 sc-205636A | 1 g 5 g | $82.00 $173.00 | 1 | |
Clomiphene, a selective estrogen receptor modulator (SERM), indirectly impacts SHBG levels by altering estrogen receptor signaling. It acts as an estrogen receptor antagonist in certain tissues, disrupting estrogen-mediated transcriptional activation, including that of SHBG. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $256.00 | 18 | |
Tamoxifen, a selective estrogen receptor modulator (SERM), indirectly influences SHBG levels by modulating estrogen receptor activity. It acts as an estrogen receptor antagonist in specific tissues, disrupting estrogen-mediated transcriptional activation, including that of SHBG. | ||||||